218 related articles for article (PubMed ID: 35159281)
21. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
[TBL] [Abstract][Full Text] [Related]
22. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
23. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
[TBL] [Abstract][Full Text] [Related]
24. VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma.
Lessi F; Mazzanti CM; Tomei S; Di Cristofano C; Minervini A; Menicagli M; Apollo A; Masieri L; Collecchi P; Minervini R; Carini M; Bevilacqua G
Med Oncol; 2014 Mar; 31(3):840. PubMed ID: 24446253
[TBL] [Abstract][Full Text] [Related]
25. Dominant-negative HIF-3 alpha 4 suppresses VHL-null renal cell carcinoma progression.
Maynard MA; Evans AJ; Shi W; Kim WY; Liu FF; Ohh M
Cell Cycle; 2007 Nov; 6(22):2810-6. PubMed ID: 17998805
[TBL] [Abstract][Full Text] [Related]
26. Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α.
Fan Y; Li H; Ma X; Gao Y; Bao X; Du Q; Ma M; Liu K; Yao Y; Huang Q; Zhang Y; Zhang X
Oncotarget; 2016 Apr; 7(14):18280-94. PubMed ID: 26943772
[TBL] [Abstract][Full Text] [Related]
27. Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells.
Malec V; Coulson JM; Urbé S; Clague MJ
J Proteome Res; 2015 Dec; 14(12):5263-72. PubMed ID: 26506913
[TBL] [Abstract][Full Text] [Related]
28. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
[TBL] [Abstract][Full Text] [Related]
29. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor.
Nyhan MJ; O'Sullivan GC; McKenna SL
Biochem Soc Trans; 2008 Jun; 36(Pt 3):472-8. PubMed ID: 18481984
[TBL] [Abstract][Full Text] [Related]
30. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas.
Cuevas Y; Hernández-Alcoceba R; Aragones J; Naranjo-Suárez S; Castellanos MC; Esteban MA; Martín-Puig S; Landazuri MO; del Peso L
Cancer Res; 2003 Oct; 63(20):6877-84. PubMed ID: 14583486
[TBL] [Abstract][Full Text] [Related]
31. Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.
Kucejova B; Peña-Llopis S; Yamasaki T; Sivanand S; Tran TA; Alexander S; Wolff NC; Lotan Y; Xie XJ; Kabbani W; Kapur P; Brugarolas J
Mol Cancer Res; 2011 Sep; 9(9):1255-65. PubMed ID: 21798997
[TBL] [Abstract][Full Text] [Related]
32. Synergy between von Hippel-Lindau and P53 contributes to chemosensitivity of clear cell renal cell carcinoma.
Zhao Z; Chen C; Lin J; Zeng W; Zhao J; Liang Y; Tan Q; Yang C; Li H
Mol Med Rep; 2016 Sep; 14(3):2785-90. PubMed ID: 27485825
[TBL] [Abstract][Full Text] [Related]
33. Zafirlukast Induces VHL- and HIF-2α-Dependent Oxidative Cell Death in 786-O Clear Cell Renal Carcinoma Cells.
Wolf C; Smith S; van Wijk SJL
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408930
[TBL] [Abstract][Full Text] [Related]
34. Homotypic association between tumour-associated VHL proteins leads to the restoration of HIF pathway.
Chung J; Roberts AM; Chow J; Coady-Osberg N; Ohh M
Oncogene; 2006 May; 25(21):3079-83. PubMed ID: 16407835
[TBL] [Abstract][Full Text] [Related]
35. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
36. Quantitative proteomics to study a small molecule targeting the loss of von Hippel-Lindau in renal cell carcinomas.
Bouhamdani N; Joy A; Barnett D; Cormier K; Léger D; Chute IC; Lamarre S; Ouellette R; Turcotte S
Int J Cancer; 2017 Aug; 141(4):778-790. PubMed ID: 28486780
[TBL] [Abstract][Full Text] [Related]
37. NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas.
Pantuck AJ; An J; Liu H; Rettig MB
Cancer Res; 2010 Jan; 70(2):752-61. PubMed ID: 20068166
[TBL] [Abstract][Full Text] [Related]
38. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
[TBL] [Abstract][Full Text] [Related]
39. Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene.
Baldewijns MM; van Vlodrop IJ; Smits KM; Vermeulen PB; Van den Eynden GG; Schot F; Roskams T; van Poppel H; van Engeland M; de Bruïne AP
Cell Oncol; 2009; 31(5):371-82. PubMed ID: 19759417
[TBL] [Abstract][Full Text] [Related]
40. Proteomic analysis of signaling network regulation in renal cell carcinomas with differential hypoxia-inducible factor-2α expression.
Nagaprashantha LD; Talamantes T; Singhal J; Guo J; Vatsyayan R; Rauniyar N; Awasthi S; Singhal SS; Prokai L
PLoS One; 2013; 8(8):e71654. PubMed ID: 23940778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
